Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Total Debt (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Total Debt readings, the most recent being $473605.0 for Q2 2017.

  • For the quarter ending Q2 2017, Total Debt fell 94.63% year-over-year to $473605.0, compared with a TTM value of $473605.0 through Jun 2017, down 94.63%, and an annual FY2016 reading of $4.2 million, down 11.53% over the prior year.
  • Total Debt hit $473605.0 in Q2 2017 for Lisata Therapeutics, down from $3.4 million in the prior quarter.
  • The five-year high for Total Debt was $15.0 million in Q4 2014, with the low at $473605.0 in Q2 2017.
  • Median Total Debt over the past 5 years was $3.6 million (2013), compared with a mean of $5.2 million.
  • The sharpest move saw Total Debt skyrocketed 2723.99% in 2014, then tumbled 94.63% in 2017.
  • Year by year, Total Debt stood at $531164.0 in 2013, then soared by 2723.99% to $15.0 million in 2014, then crashed by 68.3% to $4.8 million in 2015, then fell by 11.53% to $4.2 million in 2016, then crashed by 88.74% to $473605.0 in 2017.
  • According to Business Quant data, Total Debt over the past three periods came in at $473605.0, $3.4 million, and $4.2 million for Q2 2017, Q1 2017, and Q4 2016 respectively.